Mifepristone
FDA-approved product (tablet, oral), marketed as Korlym, Mifeprex, Mifepristone.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cushing syndrome
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Progesterone receptor modulators
- FDA pharmacologic class
- Progestin Antagonist FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA55.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli42.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae39.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis43.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Mifepristone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- PimozideExisting use: Psychosis, Tics, Tourette syndrome55.1% AI-predicted activityagainst E. coli15 registered studies
- VenetoclaxExisting use: Cancer, Chronic lymphocytic leukemia, Neoplasm55.0% AI-predicted activityagainst E. coli50+ registered studies
- RepotrectinibExisting use: Cancer, Neoplasm55.0% AI-predicted activityagainst E. coli17 registered studies
- Telotristat EtiprateExisting use: Carcinoid tumor, Diarrhea, Neuroendocrine neoplasm54.9% AI-predicted activityagainst E. coli27 registered studies
- Prasugrel HydrochlorideExisting use: Acute coronary syndrome, Hemorrhage, Intermediate coronary syndrome and 1 more54.8% AI-predicted activityagainst E. coli50+ registered studies
- Bosutinib MonohydrateExisting use: Chronic myelogenous leukemia, Myeloid leukemia54.6% AI-predicted activityagainst E. coli2 registered studies
- Ribociclib SuccinateExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 1 more54.5% AI-predicted activityagainst E. coli1 registered study
- Ergoloid MesylatesExisting use: Cardiovascular disease54.5% AI-predicted activityagainst E. coli2 registered studies
- CabotegravirExisting use: HIV infection, HIV-1 infection, Viral disease54.4% AI-predicted activityagainst E. coli50+ registered studies
- RisperidoneExisting use: Aggressive behavior, Autism, Bipolar disorder and 4 more54.2% AI-predicted activityagainst E. coli50+ registered studies
- LorlatinibExisting use: Cancer, Lymphoma, Neoplasm and 1 more54.1% AI-predicted activityagainst E. coli50+ registered studies
- TelaprevirExisting use: Chronic hepatitis C virus infection, Viral disease53.9% AI-predicted activityagainst E. coli50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Efficacy of Mifepristone in Males With Type 2 Diabetes Mellitus
NCT03052400 · start 2017-02-03
Registered record
- Registry ID
- NCT03052400
- Conditions
- Type 2 Diabetes Mellitus; Insulin Resistance
- Interventions
- Mifepristone 600 mg daily; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 2017-02-03
- Completion
- 2021-05-31
- Enrolment
- 8
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionType 2 Diabetes Mellitus; Insulin ResistanceInterventionMifepristone 600 mg daily; PlaceboPhasePhase 2Registry statusTerminatedMifepristone and Misoprostol Compared With Misoprostol Alone for Second Trimester Abortion
NCT03044093 · start 2017-01
Registered record
- Registry ID
- NCT03044093
- Conditions
- Second Trimester Abortion
- Interventions
- Mifepristone; Placebo; Misoprostol
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Unknown
- Start
- 2017-01
- Completion
- 2019-01
- Enrolment
- 200
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSecond Trimester AbortionInterventionMifepristone; Placebo; MisoprostolPhasePhase 4Registry statusUnknown24-hour Mifepristone and Buccal Versus Mifepristone and Vaginal Misoprostol for Cervical Preparation for D&E
NCT03134183 · start 2016-11-19
Registered record
- Registry ID
- NCT03134183
- Conditions
- Abortion, Second Trimester
- Interventions
- Vaginal Misoprostol; Buccal Misoprostol
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2016-11-19
- Completion
- 2017-08-01
- Enrolment
- 70
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAbortion, Second TrimesterInterventionVaginal Misoprostol; Buccal MisoprostolPhasePhase 4Registry statusCompletedMifepristone Induction for Fetal Demise
NCT02620904 · start 2016-07-14
Registered record
- Registry ID
- NCT02620904
- Conditions
- Intrauterine Fetal Demise; Fetal Death
- Interventions
- Mifepristone; placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Terminated
- Start
- 2016-07-14
- Completion
- 2020-01
- Enrolment
- 9
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionIntrauterine Fetal Demise; Fetal DeathInterventionMifepristone; placeboPhasePhase 4Registry statusTerminatedEfficacy of Mifepristone - Prostaglandin Analogue Combination in Medical Termination of Pregnancy Beyond 7 Weeks of Amenorrhea
NCT02614781 · start 2015-11
Registered record
- Registry ID
- NCT02614781
- Conditions
- Medical Termination of Pregnancy
- Interventions
- Not recorded
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2015-11
- Completion
- 2016-05
- Enrolment
- 892
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMedical Termination of PregnancyInterventionNot recordedPhaseNot recordedRegistry statusCompletedSelf-Assessment of Medical Abortion Outcome Using Serial Multi-level Pregnancy Tests
NCT02570204 · start 2015-09
Registered record
- Registry ID
- NCT02570204
- Conditions
- Medical Abortion
- Interventions
- Self-assessment
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2015-09
- Completion
- 2016-12
- Enrolment
- 343
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMedical AbortionInterventionSelf-assessmentPhaseNot applicableRegistry statusCompletedOutpatient Medical Abortion With Mifepristone and Misoprostol Through 77 Days of Gestation
NCT02314754 · start 2014-12
Registered record
- Registry ID
- NCT02314754
- Conditions
- Medical Abortion
- Interventions
- Mifepristone followed by misoprostol 24-48 hours later
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2014-12
- Completion
- 2016-04
- Enrolment
- 719
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMedical AbortionInterventionMifepristone followed by misoprostol 24-48 hours laterPhasePhase 4Registry statusCompletedCORT125134 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)
NCT03508635 · start 2014-09
Registered record
- Registry ID
- NCT03508635
- Conditions
- Healthy
- Interventions
- CORT125134; Matching Placebo of CORT125134; Mifepristone; Prednisone; Glucose
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2014-09
- Completion
- 2015-12
- Enrolment
- 130
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionCORT125134; Matching Placebo of CORT125134; Mifepristone; Prednisone +1 morePhasePhase 1Registry statusCompletedA Pilot of an Outpatient Regimen of Medical Abortion With Mifepristone and Sublingual Misoprostol in the 11 and 12 Weeks
NCT02720991 · start 2014-07
Registered record
- Registry ID
- NCT02720991
- Conditions
- Abortion, 3 Months
- Interventions
- Mifepristone; Sublingual misoprostol
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2014-07
- Completion
- 2015-04
- Enrolment
- 50
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAbortion, 3 MonthsInterventionMifepristone; Sublingual misoprostolPhasePhase 4Registry statusCompletedEffects of Mifepristone on Biomarkers of Metabolic Function and Neuropsychological Performance Among Middle-Aged and Older Individuals
NCT01988610 · start 2013-10
Registered record
- Registry ID
- NCT01988610
- Conditions
- Depression
- Interventions
- 28 days treatment with Mifepristone.
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2013-10
- Completion
- 2017-02
- Enrolment
- 23
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDepressionIntervention28 days treatment with Mifepristone.PhasePhase 1Registry statusCompletedCervical Preparation Before Dilation and Evacuation
NCT01751087 · start 2013-01
Registered record
- Registry ID
- NCT01751087
- Conditions
- Abortion, Induced
- Interventions
- Mifepristone; misoprostol; Osmotic dilators; placebo; placebo
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2013-01
- Completion
- 2014-06
- Enrolment
- 300
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAbortion, InducedInterventionMifepristone; misoprostol; Osmotic dilators; placebo +1 morePhaseNot applicableRegistry statusCompletedMifepristone and Misoprostol for Mid-trimester Termination of Pregnancy in Armenia
NCT01766388 · start 2012-12
Registered record
- Registry ID
- NCT01766388
- Conditions
- Abortion in Second Trimester
- Interventions
- Not recorded
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2012-12
- Completion
- 2013-12
- Enrolment
- 120
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAbortion in Second TrimesterInterventionNot recordedPhaseNot recordedRegistry statusCompletedNovel Therapeutics in Posttraumatic Stress Disorder (PTSD): A Randomized Clinical Trial of Mifepristone
NCT01739335 · start 2012-11-19
Registered record
- Registry ID
- NCT01739335
- Conditions
- Stress Disorders, Post-Traumatic
- Interventions
- Mifepristone Oral Tablet [Korlym]; Placebo Oral Tablet
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2012-11-19
- Completion
- 2016-11-16
- Enrolment
- 81
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionStress Disorders, Post-TraumaticInterventionMifepristone Oral Tablet [Korlym]; Placebo Oral TabletPhasePhase 2Registry statusCompletedMifepristone Versus Misoprostol for Cervical Preparation Prior to Surgical Abortion Between 11 to 15 Weeks
NCT01636063 · start 2012-06
Registered record
- Registry ID
- NCT01636063
- Conditions
- Induced Abortion; Abortion Techniques; Mifepristone; Misoprostol
- Interventions
- Mifepristone; Misoprostol
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Terminated
- Start
- 2012-06
- Completion
- 2014-05
- Enrolment
- 42
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInduced Abortion; Abortion Techniques; Mifepristone; MisoprostolInterventionMifepristone; MisoprostolPhaseNot applicableRegistry statusTerminatedAcceptability and Feasibility of a Demedicalized Medical Abortion Regimen in the Caucasus
NCT02219100 · start 2010-11
Registered record
- Registry ID
- NCT02219100
- Conditions
- Abortion, First Trimester
- Interventions
- Home administration of 200 mg mifepristone
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2010-11
- Completion
- 2011-11
- Enrolment
- 613
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAbortion, First TrimesterInterventionHome administration of 200 mg mifepristonePhaseNot applicableRegistry statusCompleted